[Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer]

Xiao-kui Yang; Hui Xing; Qing-lei Gao; Wei Wang; Su-fang Wu; Yun-ping Lu; Shi-xuan Wang; Ding Ma

[Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer]

Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):425-8.

[Article in Chinese]

Authors

Xiao-kui Yang¹, Hui Xing, Qing-lei Gao, Wei Wang, Su-fang Wu, Yun-ping Lu, Shi-xuan Wang, Ding Ma

Affiliation

¹ Department of Obstetrics & Gynecology, Tongji Hospital, Tongji Medical College, University of Huazhong Science and Technology. Wuhan 430030, China.

PMID: 14575561

Abstract

Objective: To study the mechanism of multidrug resistance and its reversal by mdr-1 ribozyme in human ovarian cancer.

Methods: The expression of mdr-1 and p-glycoprotein (p-gp) was studied by confocal laser microscope (Confocal), RT-PCR and Western blot analysis in adriamycin-resistant human ovarian cancer cell line (A2780/ADM) and adriamycin-sensitive one (A2780). The mdr-1 ribozyme was transfected into the A2780/ADM by Lipofectamine 2000 to overcome the multidrug resistance in ovarian cancer.

Results: The expression of mdr-1 mRNA and p-gp in A2780/ADM was significantly higher than that in A2780. The expression of mdr-1 mRNA and p-gp in A2780/ADM was lowered after being transfected by mdr-1 ribozyme.

Conclusion: Multidrug resistance of A2780/ADM, possibly being caused by overexpression of mdr-1 gene, can be partially reversed by mdr-1 ribozyme.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

ATP Binding Cassette Transporter, Subfamily B, Member 1 / analysis
ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Female
Humans
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / metabolism
RNA, Catalytic / therapeutic use*
RNA, Messenger / analysis

Substances

ATP Binding Cassette Transporter, Subfamily B, Member 1
RNA, Catalytic
RNA, Messenger